<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00520598</url>
  </required_header>
  <id_info>
    <org_study_id>V505-001</org_study_id>
    <secondary_id>2007_567</secondary_id>
    <nct_id>NCT00520598</nct_id>
  </id_info>
  <brief_title>Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)</brief_title>
  <official_title>A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison
      to GARDASIL (TM)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean titers (GMTs) to HPV types contained in the vaccines administered in a 3-dose regimen</measure>
    <time_frame>4 weeks post dose 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers (GMTs) to HPV types contained in the vaccines administered in a 2-dose regimen</measure>
    <time_frame>4 weeks post dose 2</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">511</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Vulvar Cancer</condition>
  <condition>Vaginal Cancer</condition>
  <condition>Genital Warts</condition>
  <condition>Human Papillomavirus Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: 0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2: 0.5 ml injection of V505 formulation 1 as 3 dose regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 3: 0.5 ml injection of V505 formulation 2 as 3 dose regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 4: 0.5 ml injection of V505 formulation 2 as 2 dose regimen and 1 Pbo injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 5: 0.5 ml injection of V505 formulation 3 as 2 dose regimen and 1 Pbo injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: V505 formulation 1</intervention_name>
    <description>0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: V505 formulation 2</intervention_name>
    <description>0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: V505 formulation 2</intervention_name>
    <description>0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: V505 formulation 3</intervention_name>
    <description>0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant</intervention_name>
    <description>0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Placebo (unspecified)</intervention_name>
    <description>0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.</description>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female between 16 to 26 years old

          -  Has never had Pap testing or have only had normal Pap test results

          -  Lifetime history of 0 to 4 sexual partners

        Exclusion Criteria:

          -  History of an abnormal cervical biopsy result; History of a positive test for HPV;
             History of external genital/vaginal warts; Currently a user of any illegal drugs or an
             alcohol abuser

          -  History of severe allergic reaction that required medical attention

          -  Are pregnant

          -  Received a marketed HPV vaccine

          -  Currently enrolled in a clinical trial

          -  Currently has (or has a history of) certain medical conditions or is currently taking
             or has taken certain medications (details will be discussed at time of consent)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2007</study_first_submitted>
  <study_first_submitted_qc>August 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2007</study_first_posted>
  <last_update_submitted>November 25, 2015</last_update_submitted>
  <last_update_submitted_qc>November 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

